Billionaire Profile
K
Global Rank
#602

Image: Unknown Author | Public domain | via Wikimedia Commons

Katharina von Baumbach

CEO, Pharma
GERMANY
Real-Time Net Worth
$6.636B
Estimated based on Pharma stock value as of April 20, 2026
0% (24h)
Age
26
Source
Pharma
Industry
Healthcare
Citizenship
GERMANY

Biography

Katharina von Baumbach, a German billionaire, is a prominent figure in the pharmaceutical industry. Born into the family that owns Boehringer Ingelheim, one of the world's largest privately held pharmaceutical companies, she is part of the fourth generation involved in the family business. Her wealth is derived from her inherited stake in Boehringer Ingelheim, which specializes in innovative medicines for both humans and animals. With a net worth of $6.6 billion, she ranks among the world's wealthiest individuals. Her role is defined by generational stewardship and fiduciary oversight of the company, ensuring its long-term commitment to research and development and patient care.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/20/2026

Wealth Over Time

In-Depth Profile

Early Life

Katharina von Baumbach's story begins with her birth into a family deeply rooted in the pharmaceutical industry. As a member of the von Baumbach family, she is an heir to Boehringer Ingelheim, a company founded in 1885 by Albert Boehringer. This legacy has been passed down through generations, maintaining the company's private ownership and commitment to innovation.

Rise to Success

Katharina's wealth and influence stem from her significant stake in Boehringer Ingelheim. While specific details of her career path aren't widely available, her role is primarily focused on the generational stewardship and fiduciary oversight of the family's assets. The company has a global presence, employing over 53,000 people and operating in 130 markets. Boehringer Ingelheim is known for its research and development of medicines treating various conditions, including COPD, anti-coagulation, and type 2 diabetes.

Key Business Strategies

Boehringer Ingelheim's success is underpinned by its commitment to long-term investment in research and development. This strategy, combined with its private ownership structure, allows the company to focus on innovation without the short-term pressures of the public market. Katharina, along with her family, ensures this commitment continues, supporting the company's mission to discover and manufacture innovative healthcare products.

Philanthropy

Katharina von Baumbach's social impact stems from Boehringer Ingelheim's mission to discover and manufacture innovative healthcare products globally. Her family supports scientific research and educational initiatives through the company's foundation. This structural contribution ensures that the company remains committed to R&D and patient care for years to come.